{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:35:00Z","timestamp":1787070900415,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Donor lymphocyte infusions (DLIs) are often recommended products after allogeneic hematopoietic stem cell transplant to increase graft \u2013 versus \u2013 leukemia effect. More success rate of DLI has been reported in relapsed posttransplant chronic myeloid leukemia. Whatever the indication for DLI, mortality related to post-DLI infusion is 5%\u201320%, and more than one-third of patients will develop acute and\/or chronic graft versus host disease (GVHD) after DLI. We report two cases where DLIs were used for residual disease after posttransplant. Both of DLI went uneventful. None of the patient\u2019s developed signs of GVHD postinfusion. Although both patients expired with different causes, none were related to DLI infusion. Information from published literature suggests that DLI should be administered early after relapse or as a prophylactic strategy in patients receiving T-cell-depleted grafts, and patients with aggressive diseases may benefit from disease reduction before DLI. However, further evidence is required to evaluate its efficacy, especially in relapsed or residual hematological malignancies.<\/jats:p>","DOI":"10.4103\/ajts.ajts_211_23","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T06:01:22Z","timestamp":1719208882000},"page":"124-127","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Donor lymphocyte infusions: An experience from a tertiary care center of North India"],"prefix":"10.4103","volume":"18","author":[{"given":"Divjot Singh","family":"Lamba","sequence":"first","affiliation":[{"name":"Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parmatma Prasad","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Hans","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Khadwal","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology and Medical Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratti Ram","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1056\/NEJMp078166","article-title":"Hematopoietic-cell transplantation at 50","volume":"357","author":"Appelbaum","year":"2007","journal-title":"N Engl J Med"},{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.transci.2016.05.011","article-title":"Donor lymphocyte infusion after allogeneic stem cell transplantation","volume":"54","author":"Castagna","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.blre.2012.11.002","article-title":"Donor lymphocyte infusions for relapse after allogeneic transplantation:When, if and for whom?","volume":"27","author":"Chang","year":"2013","journal-title":"Blood Rev"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.bbmt.2019.03.004","article-title":"Clearance of hematologic malignancies by allogeneic cytokine-induced killer cell or donor lymphocyte infusions","volume":"25","author":"Merker","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1993.11.3.513","article-title":"Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation","volume":"11","author":"B\u00e4r","year":"1993","journal-title":"J Clin Oncol"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation:Separation of graft-versus-leukemia responses from graft-versus-host disease","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"key":"R8-20240830","first-page":"663","article-title":"A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation","volume":"91","author":"Weisser","year":"2006","journal-title":"Haematologica"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ctrv.2010.03.004","article-title":"Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited","volume":"36","author":"Deol","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","article-title":"Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia:A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"R11-20240830","first-page":"669","article-title":"Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia","volume":"18","author":"Rond\u00f3n","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/imt.13.31","article-title":"Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies","volume":"5","author":"El-Jurdi","year":"2013","journal-title":"Immunotherapy"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/bmt.2016.104","article-title":"Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell all after allogeneic hematopoietic cell transplant","volume":"51","author":"Ueda","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"e28187","DOI":"10.4161\/onci.28187","article-title":"Understanding anti-leukemia responses to donor lymphocyte infusion","volume":"3","author":"Bachireddy","year":"2014","journal-title":"Oncoimmunology"}],"container-title":["Asian Journal of Transfusion Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ajts.ajts_211_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:34Z","timestamp":1787067514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ajts.ajts_211_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ajts.ajts_211_23","relation":{},"ISSN":["0973-6247","1998-3565"],"issn-type":[{"value":"0973-6247","type":"print"},{"value":"1998-3565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-10-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}